Home > Insider Trading > Filing (0000950103-11-001962)

Filing Details

Accession Number:: 0000950103-11-001962
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-05-20 18:15:46
Reporting Period:: 2011-05-18

Filing Date:: 2011-05-20
Accepted Time:: 2011-05-20 18:15:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1369868	China Biologic Products Inc.	CBPO	Biological Products, (No Disgnostic Substances) (2836)	752308816

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
929408	Warburg Pincus & Co	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1162870	Warburg Pincus Llc	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1220638	Joseph Landy	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1239318	R Charles Kaye	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1322709	Warburg Pincus Partners Llc	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1414561	Warburg Pincus X, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1414564	Warburg Pincus X Llc	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1414565	Warburg Pincus Private Equity X, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1451560	Warburg Pincus X Partners, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-05-18	38,770	$14.21	4,858,770	No	4	P	Direct
Common Stock	Acquisiton	2011-05-19	28,751	$14.66	4,887,521	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in the open market at prices ranging from $13.57 to $14.50, inclusive. The Warburg Pincus Reporting Persons (as defined below) undertake to provide to any securityholders of China Biologic Products, Inc. (the "Issuer") or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) and footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in the open market at prices ranging from $14.40 to $14.96, inclusive.
Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X"), is the holder of an aggregate of 4,736,008 shares of common stock, $0.0001 par value per share (the "Common Stock"), of the Issuer. Warburg Pincus X Partners, L.P., a Delaware limited partnership ("WPP X" and together with WP X, the "Funds"), is the holder of an aggregate of 151,513 shares of Common Stock of the Issuer. By reason of the provisions of Rule 16a-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), Warburg Pincus X, L.P., a Delaware limited partnership ("WP X LP") and the sole general partner of each of the Funds, Warburg Pincus X LLC, a Delaware limited liability company ("WP X LLC") and the sole general partner of WP X LP, Warburg Pincus Partners, LLC, a New York limited liability company ("WPP LLC") and the sole member of WP X LLC, Warburg Pincus & Co., a New York general partnership ("WP") (continued on footnote 4)
and the managing member of WPP LLC, Warburg Pincus LLC, a New York limited liability company ("WP LLC") that manages each of the Funds, and Messrs. Charles R. Kaye and Joseph P. Landy, each a Managing General Partner of WP and Co-President and Managing Member of WP LLC, may be deemed to be the beneficial owner of the shares of Common Stock of the Issuer held by the Funds. Each of the Funds, WP X LP, WP X LLC, WP Partners, WP, WP LLC, and Messrs. Charles R. Kaye and Joseph P. Landy is a "Reporting Person" and collectively, the "Warburg Pincus Reporting Persons."
Information with respect to each of the Warburg Pincus Reporting Persons is given solely by such Warburg Pincus Reporting Person, and no Warburg Pincus Reporting Person has responsibility for the accuracy or completeness of information supplied by another Warburg Pincus Reporting Person.
Pursuant to Rule 16a-1(a)(4) of the Exchange Act each of the Warburg Pincus Reporting Persons, other than the Funds, herein states that this Form 4 shall not be deemed an admission that it or he is the beneficial owner of any of the shares of Common Stock of the Issuer covered by this Form 4. Each of WP X LP, WP X LLC, WPP LLC, WP, WP LLC, and Messrs. Kaye and Landy disclaims beneficial ownership of the Common Stock of the Issuer, except to the extent of its or his pecuniary interest in such shares of Common Stock.